Bill Few Associates Inc. Buys 1,283 Shares of Organon & Co. (NYSE:OGN)

Bill Few Associates Inc. boosted its stake in shares of Organon & Co. (NYSE:OGN) by 10.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 13,866 shares of the company’s stock after buying an additional 1,283 shares during the period. Bill Few Associates Inc.’s holdings in Organon & Co. were worth $207,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of OGN. Mercer Global Advisors Inc. ADV raised its holdings in shares of Organon & Co. by 1.8% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 31,086 shares of the company’s stock worth $674,000 after acquiring an additional 546 shares in the last quarter. Sippican Capital Advisors increased its position in Organon & Co. by 4.3% in the third quarter. Sippican Capital Advisors now owns 15,230 shares of the company’s stock worth $291,000 after purchasing an additional 627 shares during the last quarter. Commerce Bank raised its stake in Organon & Co. by 5.5% during the third quarter. Commerce Bank now owns 12,168 shares of the company’s stock valued at $233,000 after purchasing an additional 637 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock valued at $41,000 after purchasing an additional 672 shares during the last quarter. Finally, Graypoint LLC grew its stake in shares of Organon & Co. by 6.2% in the 3rd quarter. Graypoint LLC now owns 14,555 shares of the company’s stock worth $278,000 after buying an additional 853 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Stock Performance

NYSE OGN opened at $15.88 on Thursday. The business’s 50 day moving average price is $15.32 and its 200-day moving average price is $18.13. Organon & Co. has a fifty-two week low of $13.87 and a fifty-two week high of $23.10. The company has a market cap of $4.09 billion, a P/E ratio of 3.15, a P/E/G ratio of 0.87 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. During the same period in the previous year, the firm earned $0.78 earnings per share. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. Sell-side analysts predict that Organon & Co. will post 3.82 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Tuesday, November 12th were given a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 7.05%. The ex-dividend date was Tuesday, November 12th. Organon & Co.’s dividend payout ratio (DPR) is currently 22.22%.

Analyst Upgrades and Downgrades

Separately, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $21.33.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.